PRAME and leukemia: Due to its highly tumor-specific expression pattern and more importantly, its well defined immunogenicity as demonstrated by specific killing of PRAME-expressing leukemia cells by PRAME antigen-specific CTL clones, PRAME has been recognized as a promising target for anti-leukemia immunotherapy [8], [9], [10].